Exelixis, Inc.
EXELExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Drugs in Pipeline
12
Phase 3 Programs
10
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
EXEL Earnings Report
EPS Est: $0.75 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How EXEL's past catalysts played out
Cabozantinib
Solid Tumors
prednisone
Prostate Cancer
Everolimus
Pancreatic Neuroendocrine Tumor (pNET)
Cabozantinib tablets
Renal Cell Carcinoma
Abiraterone Acetate
Metastatic Prostate Cancer
XL092
Non-Clear Cell Renal Cell Carcinoma
XL184
Glioblastoma Multiforme
Sorafenib
Hepatocellular Carcinoma
Regorafenib
Colorectal Cancer
Zanzalintinib
Head and Neck Squamous Cell Carcinoma
erlotinib
Carcinoma, Non-Small-Cell Lung
XL820
Gastrointestinal Stromal Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cabozantinib | Phase 3 | Solid Tumors | - | - |
prednisone | Phase 3 | Prostate Cancer | - | - |
Everolimus | Phase 3 | Pancreatic Neuroendocrine Tumor (pNET) | - | - |
Cabozantinib tablets | Phase 3 | Renal Cell Carcinoma | - | - |
Abiraterone Acetate | Phase 3 | Metastatic Prostate Cancer | - | - |
XL092 | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | - | - |
XL184 | Phase 3 | Glioblastoma Multiforme | - | - |
Sorafenib | Phase 3 | Hepatocellular Carcinoma | - | - |
Regorafenib | Phase 3 | Colorectal Cancer | - | - |
Zanzalintinib | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
erlotinib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
XL820 | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Exelixis, Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in Exelixis, Inc.'s (EXEL) pipeline across Phase 3, Phase 2. Its lead program is Cabozantinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Exelixis, Inc.'s next FDA catalyst?→
Exelixis, Inc.'s (EXEL) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EXEL biotech catalysts?→
Add EXEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Exelixis, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.